Complement 3 and 4 impact in osteoarthritis.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-02-01 Epub Date: 2025-02-02 DOI:10.1080/17520363.2024.2409062

Lifang Wang

引用次数: 0

Abstract

Aim: To investigate the association between serum complement 3 and 4 (C3 and C4) levels and clinical characteristics in osteoarthritis (OA) patients.Methods: This retrospective study included 361 OA patients divided into groups based on complement levels. Clinical data and laboratory test results, including C3, C4, ESR and CRP levels, were analyzed using non-parametric tests, Spearman correlation and multivariate regression.Results: The AC-OA group had lower PA, C3, C4, ESR, CRP and IgA levels compared with controls. C3 levels were positively correlated with ESR (r = 0.260, p < 0.001) and CRP (r = 0.243, p < 0.001). C4 levels also correlated with ESR (r = 0.175, p = 0.001) and CRP (r = 0.263, p < 0.001) and were significantly associated with the number of affected joints.Conclusion: Serum C4 levels are effective indicators of disease activity in OA, particularly in terms of joint involvement and CRP levels, while C3 levels showed no significant association. These findings suggest a potential role for C4 in predicting OA activity.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.